Depo-Nisolone is a medicine containing the active ingredient(s) methylprednisolone. On this page you will find out more about Depo-Nisolone, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: methylprednisolone
Information for medicine and pack size:
Depo-Nisolone 40 mg/mL injection suspension, 5 x 1 mL vials
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS AS AT 17 NOVEMBER 2004: A.For Intramuscular Administration. When oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-NISOLONE is indicated as follows: 1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Congenital adrenal hyperplasia. Hypercalcaemia associated with cancer. Non-suppurative thyroiditis. 2. Rheumatic Disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Epicondylitis. Synovitis of osteoarthritis. Acute non-specific tenosynovitis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. Acute and subacute bursitis. 3. Collagen Diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. Systemic dermatomyositis (polymyositis). 4. Dermatological Diseases. Pemphigus. Bullous dermatitis herpetiformis. Severe erythema multiforme (Stevens-Johnson Syndrome). Severe seborrhoeic dermatitis. Exfoliative dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Drug hypersensitivity reactions. Contact dermatitis.Urticarial transfusion reactions. Atopic dermatitis. Acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). Serum sickness. Seasonal or perennial allergic rhinitis. 6. Ophthalmic Diseases. Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Sympathetic ophthalmia. Iritis, iridocyclitis. Anterior segment inflammation. Chorioretinitis. Allergic conjunctivitis. Diffuse posterior uveitis. Allergic corneal marginal ulcers. Optic neuritis. Keratitis. 7. Gastrointestinal Diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases.Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy. Aspiration pneumonitis. Loeffler's Syndrome not manageable by other means. 9. Haematological Disorders. Acquired (autoimmune) haemolytic anaemia. Erythroblastopenia (RBC anaemia). Secondary thrombocytopenia in adults. Congenital (erythroid) hypoplastic anaemia. 10. Neoplastic Diseases. For palliative management of: Leukaemias and lymphomas in adults. Acute leukaemia in childhood. 11. Oedematous States. To induce diuresis or remission of proteinuria in the nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythematosus. 12. Nervous System. Acute exacerbations of multiple sclerosis. 13. Miscellaneous. Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy. Trichinosis with neurological or myocardial involvement. B. For Intra-Articular Or Soft Tissue Administration DEPO-NISOLONE is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Epicondylitis. Rheumatoid arthritis. Acute non-specific tenosynovitis. Acute and subacute bursitis. Post-traumatic osteoarthritis. Acute gouty arthritis. C. For Intralesional Administration. DEPO-NISOLONE is indicated for intralesional use in the following conditions: Keloids.Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. Localised hypertrophic, infiltrated inflammatory lesions of Licen Planus, psoriatic plaques, Granuloma Annulare and Lichen Simplex Chronicus (neurodermatitis). DEPO-NISOLONE may also be useful in cystic tumours of an aponeurosis or tendon (ganglia).
Table of characteristics
|Visual appearance||White to off white suspension when mixed|
|Dosage Form||Injection, suspension|
|Route of administration||Intramuscular|
1 mL X 1: Prescription Only Medicine, or Prescription Animal Remedy
1mL X 5: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||Do not Freeze|
|Life time||3 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.